Negative impact of immunoparesis in response to anti-SARS-CoV-2 mRNA vaccination of patients with multiple myeloma.
COVID-19
M-protein
Multiple myeloma
Prediction
Vaccine
Journal
International journal of hematology
ISSN: 1865-3774
Titre abrégé: Int J Hematol
Pays: Japan
ID NLM: 9111627
Informations de publication
Date de publication:
12 Dec 2023
12 Dec 2023
Historique:
received:
03
07
2023
accepted:
13
11
2023
revised:
31
10
2023
medline:
12
12
2023
pubmed:
12
12
2023
entrez:
11
12
2023
Statut:
aheadofprint
Résumé
Multiple myeloma reduces cellular and humoral immunity. Optimal prediction of antibody response to anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in patients with MM and related disorders is essential to prevent coronavirus disease 2019 (COVID-19) during the SARS-CoV-2 pandemic. This study analyzed the humoral response to the anti-SARS-CoV-2 messenger ribonucleic acid (mRNA) vaccine and its associated factor in 83 patients from June to November 2021 at seven member institutions of the Kyoto Clinical Hematology Study Group. SARS-CoV-2 neutralizing antibody (nAb) was measured from 12 to 210 days. The result revealed that 40 (48.2%) patients with MM and 59 (100%) healthy controls became seropositive after vaccination. Receiver operating characteristic curve analysis identified serum immunoglobulin (Ig) M of > 18 mg/dL at vaccination as the optimal threshold level associated with seropositivity in the whole cohort. Moreover, the multivariate analysis identified serum IgM of > 18 mg/dL as the independent predictor for a favorable response. Serum IgA level was positively associated with vaccine response in a sub-cohort. Our findings indicate a significant association between immunoparesis and impaired humoral response against mRNA vaccination, including that against SARS-CoV-2, and that serum non-M-protein Ig levels can serve as surrogate biomarkers of nAb production ability.
Identifiants
pubmed: 38082201
doi: 10.1007/s12185-023-03680-1
pii: 10.1007/s12185-023-03680-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. Japanese Society of Hematology.
Références
Bellamkonda N, Lambe UP, Sawant S, Nandi SS, Chakraborty C, Shukla D. Immune response to SARS-CoV-2 vaccines. Biomedicines. 2022;10(7):1464. https://doi.org/10.3390/biomedicines10071464 .
doi: 10.3390/biomedicines10071464
pubmed: 35884770
pmcid: 9312515
Federico M. How Do Anti-SARS-CoV-2 mRNA vaccines protect from severe disease? Int J Mol Sci. 2022;23(18):10374. https://doi.org/10.3390/ijms231810374 .
doi: 10.3390/ijms231810374
pubmed: 36142284
pmcid: 9499329
Pessoa de Magalhães RJ, Vidriales MB, Paiva B, Fernandez-Gimenez C, García-Sanz R, Mateos MV, et al. Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry. Haematologica. 2013;98(1):79–86. https://doi.org/10.3324/haematol.2012.067272 . (Epub 2012 Jul 6).
doi: 10.3324/haematol.2012.067272
pubmed: 22773604
pmcid: 3533663
Sugiyama A, Kurisu A, Nagashima S, Hando K, Saipova K, Akhmedova S, et al. Seroepidemiological study of factors affecting anti-spike IgG antibody titers after a two-dose mRNA COVID-19 vaccination in 3744 healthy Japanese volunteers. Sci Rep. 2022;12(1):16294. https://doi.org/10.1038/s41598-022-20747-x .
doi: 10.1038/s41598-022-20747-x
pubmed: 36175506
pmcid: 9520958
Maeda H, Saito N, Igarashi A, Ishida M, Suami K, Yagiuchi A, et al. Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections during the Delta variant epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS). Clin Infect Dis. 2022;75(11):1971–9. https://doi.org/10.1093/cid/ciac292 .
doi: 10.1093/cid/ciac292
pubmed: 35438137
pmcid: 9047210
Oyaert M, De Scheerder MA, Van Herrewege S, Laureys G, Van Assche S, Cambron M, et al. Evaluation of humoral and cellular responses in SARS-CoV-2 mRNA vaccinated immunocompromised patients. Front Immunol. 2022;13: 858399. https://doi.org/10.3389/fimmu.2022.858399.eCollection .
doi: 10.3389/fimmu.2022.858399.eCollection
pubmed: 35401575
pmcid: 8988283
Lee ARYB, Wong SY, Chai LYA, Lee SC, Lee MX, Muthiah MD, et al. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis. BMJ. 2022;376:e068632. https://doi.org/10.1136/bmj-2021-068632 .
doi: 10.1136/bmj-2021-068632
pubmed: 35236664
Onishi A, Matsumura-Kimoto Y, Mizutani S, Tsukamoto T, Fujino T, Miyashita A, et al. Impact of Treatment with Anti-CD20 monoclonal antibody on the production of neutralizing antibody against anti–SARS–CoV–2 Vaccination in Mature B-Cell Neoplasms. Infection and Drug Resistance. 2023;16:509–19. https://doi.org/10.2147/IDR.S396271.eCollection .
doi: 10.2147/IDR.S396271.eCollection
pubmed: 36721633
pmcid: 9884434
Blimark C, Holmberg E, Mellqvist UH, Landgren O, Björkholm M, Hultcrantz M, et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica. 2014;100(1):107–13. https://doi.org/10.3324/haematol.2014.107714 . (Epub 2014 Oct 24).
doi: 10.3324/haematol.2014.107714
pubmed: 25344526
Chari A, Samur MK, Martinez-Lopez J, Cook G, Biran N, Yong K, et al. Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set. Blood. 2020;136(26):3033–40. https://doi.org/10.1182/blood.2020008150 .
doi: 10.1182/blood.2020008150
pubmed: 33367546
pmcid: 7759145
Martinez-Lopez J, Hernandez-Ibarburu G, Alonso R, Sanchez-Pina JM, Zamanillo I, Lopez-Muñoz N, et al. Impact of COVID-19 in patients with multiple myeloma based on a global data network. Blood Cancer J. 2021;11(12):198. https://doi.org/10.1038/s41408-021-00588-z .
doi: 10.1038/s41408-021-00588-z
pubmed: 34893583
pmcid: 8661359
Kaneko Y, Sugiyama A, Tanaka T, Fukui K, Taguchi A, Tatsuno K, et al. The serological diversity of serum IgG/IgA/IgM against SARS-CoV-2 nucleoprotein, spike, and receptor-binding domain and neutralizing antibodies in patients with COVID-19 in Japan. Health Sci Rep. 2022;5(3): e572. https://doi.org/10.1002/hsr2.572.eCollection .
doi: 10.1002/hsr2.572.eCollection
pubmed: 35509410
pmcid: 9059222
Jeewandara C, Jayathilaka D, Gomes L, Wijewickrama A, Narangoda E, Idampitiya D, et al. SARS-CoV-2 neutralizing antibodies in patients with varying severity of acute COVID-19 illness. Sci Rep. 2021;11(1):2062. https://doi.org/10.1038/s41598-021-81629-2 .
doi: 10.1038/s41598-021-81629-2
pubmed: 33479465
pmcid: 7819970
Lau EHY, Tsang OTY, Hui DSC, Kwan MYW, Chan WH, Chiu SS, et al. Neutralizing antibody titres in SARS-CoV-2 infections. Nat Commun. 2021;12(1):63. https://doi.org/10.1038/s41467-020-20247-4 .
doi: 10.1038/s41467-020-20247-4
pubmed: 33397909
pmcid: 7782739
Legros V, Denolly S, Vogrig M, Boson B, Siret E, Rigaill J, et al. A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity. Cell Mol Immunol. 2021;18(2):318–27. https://doi.org/10.1038/s41423-020-00588-2 . (Epub 2021 Jan 6).
doi: 10.1038/s41423-020-00588-2
pubmed: 33408342
Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2012;48(3):452–8. https://doi.org/10.1038/bmt.2012.244 . (Epub 2012 Dec 3).
doi: 10.1038/bmt.2012.244
pubmed: 23208313
pmcid: 3590441
Global Change Data Lab. Oxford Martin School. Coronavirus (COVID-19) Vaccinations-Our World in Data. https://ourworldindata.org/covid-vaccinations
Ollila TA, Masel RH, Reagan JL, Lu S, Rogers RD, Paiva KJ, et al. Seroconversion and outcomes after initial and booster COVID-19 vaccination in adults with hematologic malignancies. Cancer. 2022;128(18):3319–29. https://doi.org/10.1002/cncr.34354 . (Epub 2022 Jul 11).
doi: 10.1002/cncr.34354
pubmed: 35811461
Pascale SP, Nuccorini R, Pierri T, Di Mare R, Fabio L, Lerose E, et al. Evaluation of serological response to anti-SARS-CoV-2 mRNA vaccination in hematological patients. Front Immunol. 2022;13: 892331. https://doi.org/10.3389/fimmu.2022.892331.eCollection .
doi: 10.3389/fimmu.2022.892331.eCollection
pubmed: 36003404
pmcid: 9393554
St-Pierre F, Doukas P, Boyer J, Nieves M, Ma S. CLL-211 Humoral immune response following COVID-19 vaccination in patients with chronic lymphocytic leukemia (CLL) and indolent non-hodgkin lymphoma (NHL): results from a large, single-center observational study. Clin Lymphoma Myeloma Leuk. 2022;22(Suppl 2):S273. https://doi.org/10.1016/S2152-2650(22)01335-0 .
doi: 10.1016/S2152-2650(22)01335-0
pmcid: 9489270
Tanguay M, Boutin M, Laumaea A, Salaciak M, Mendoza A, Cassis C, et al. B-cell cytopenia and time to last B-cell-depleting therapy predict response to SARS-COV-2 vaccines in patients with lymphoproliferative disorders. Vaccine. 2022;40(9):1203–7. https://doi.org/10.1016/j.vaccine.2022.01.040 . (Epub 2022 Jan 24).
doi: 10.1016/j.vaccine.2022.01.040
pubmed: 35105492
pmcid: 8784616
Chuleerarux N, Manothummetha K, Moonla C, Sanguankeo A, Kates OS, Hirankarn N, et al. Immunogenicity of SARS-CoV-2 vaccines in patients with multiple myeloma: a systematic review and meta-analysis. Blood Adv. 2022;6(24):6198–207. https://doi.org/10.1182/bloodadvances.2022008530 .
doi: 10.1182/bloodadvances.2022008530
pubmed: 36538342
pmcid: 9561400
Pilarski LM, Ruether BA, Mant MJ. Abnormal function of B lymphocytes from peripheral blood of multiple myeloma patients. Lack of correlation between the number of cells potentially able to secrete immunoglobulin M and serum immunoglobulin M levels. J Clin Invest. 1985;75(6):2024–9. https://doi.org/10.1172/JCI111921 .
doi: 10.1172/JCI111921
pubmed: 2989339
pmcid: 425563
Tete SM, Bijl M, Sahota SS, Bos NA. Immune defects in the risk of infection and response to vaccination in monoclonal gammopathy of undetermined significance and multiple myeloma. Front Immunol. 2014;5:257. https://doi.org/10.3389/fimmu.2014.00257.eCollection .
doi: 10.3389/fimmu.2014.00257.eCollection
pubmed: 24917865
pmcid: 4042361
Narita K, Nakaji S, Tabata R, Terao T, Kuzume A, Tsushima T, et al. Antibody response to COVID-19 vaccination in patients with lymphoma. Int J Hematol. 2022;115(5):728–36. https://doi.org/10.1007/s12185-022-03305-z . (Epub 2022 Feb 21).
doi: 10.1007/s12185-022-03305-z
pubmed: 35188650
pmcid: 8859496
Olteanu H, Wang HY, Chen W, McKenna RW, Karandikar NJ. Immunophenotypic studies of monoclonal gammopathy of undetermined significance. BMC Clin Pathol. 2008;8:13. https://doi.org/10.1186/1472-6890-8-13 .
doi: 10.1186/1472-6890-8-13
pubmed: 19040735
pmcid: 2606678
Reynolds JA, Faustini SE, Tosounidou S, Plant T, Ubhi M, Gilman R, et al. Anti-SARS-CoV-2 antibodies following vaccination are associated with lymphocyte count and serum immunoglobulins in SLE. Lupus. 2023;32(3):431–7. https://doi.org/10.1177/09612033231151603 . (Epub 2023 Jan 11).
doi: 10.1177/09612033231151603
pubmed: 36631440
pmcid: 9843147
Bidgood SR, Tam JC, McEwan WA, Mallery DL, James LC. Translocalized IgA mediates neutralization and stimulates innate immunity inside infected cells. Proc Natl Acad Sci USA. 2014;111(37):13463–8. https://doi.org/10.1073/pnas.1410980111 . (Epub 2014 Aug 28).
doi: 10.1073/pnas.1410980111
pubmed: 25169018
pmcid: 4169910
Rangel-Ramírez VV, Macías-Piña KA, Servin-Garrido RR, de Alba-Aguayo DR, Moreno-Fierros L, Rubio-Infante N. A systematic review and meta-analysis of the IgA seroprevalence in COVID-19 patients: is there a role for IgA in COVID-19 diagnosis or severity? Microbiol Res. 2022;263:127105. https://doi.org/10.1016/j.micres.2022.127105 .
doi: 10.1016/j.micres.2022.127105
pubmed: 35816990
pmcid: 9245367
Shi Y, Yamazaki T, Okubo Y, Uehara Y, Sugane K, Agematsu K. Regulation of aged humoral immune defense against pneumococcal bacteria by IgM memory B cell. J Immunol. 2005;175(5):3262–7. https://doi.org/10.4049/jimmunol.175.5.3262 .
doi: 10.4049/jimmunol.175.5.3262
pubmed: 16116217
Jolliffe DA, Faustini SE, Holt H, Perdek N, Maltby S, Talaei M, et al. Determinants of Antibody Responses to SARS-CoV-2 Vaccines: population-Based Longitudinal Study (COVIDENCE UK). Vaccines (Basel). 2022;10(10):1601. https://doi.org/10.3390/vaccines10101601 .
doi: 10.3390/vaccines10101601
pubmed: 36298466